Status:
COMPLETED
A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Dyslipidemias
Eligibility:
All Genders
30-80 years
Phase:
PHASE4
Brief Summary
A study of the long-term (1 year) effectiveness of atorvastatin to keep patients of high cardiovascular risk at the LDL cholesterol goal of \<115 mg/dL
Eligibility Criteria
Inclusion
- Completion of base study
- Dyslipidemia and at high risk of CHD
Exclusion
- Impaired liver function
- Gastrointestinal disease that could limit drug absorption
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2005
Estimated Enrollment :
196 Patients enrolled
Trial Details
Trial ID
NCT00644709
Start Date
September 1 2003
End Date
March 1 2005
Last Update
February 18 2021
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Antwerp, Belgium, 2018
2
Pfizer Investigational Site
Brasschaat, Belgium, 2930
3
Pfizer Investigational Site
Brussels, Belgium, 1180
4
Pfizer Investigational Site
Genk, Belgium, B-3600